Pharmaceuticals company Senores Pharmaceuticals announced Q2FY26 results Revenue: Rs 162 crore for Q2FY26, change 61% YoY. EBITDA: Rs 50 crore for Q2FY26, change 113% YoY. PAT: Rs 30 crore for Q2FY26, change 131% YoY. Swapnil Shah, Managing Director, Senores Pharmaceuticals, said: “Building on the momentum from previous quarters, we delivered a strong performance in Q2FY26, with revenues rising 61% and profit after tax growing 131% YoY. In the Regulated Markets, we launched eight new products during the quarter, achieving better-than-expected sales. With additional launches and scale-up of existing products in the coming quarters, we expect this growth momentum in the Own Products business to continue through H2 and FY27. Margins have also strengthened, supported by a higher contribution from own products, improved operating efficiency, and inherent operating leverage. With scale and productivity gains, we remain confident of sustaining our margin profile. Our Emerging Markets portfolio continued to expand, reflecting steady growth in revenues and margins on a sequential basis, alongside an increasing number of registered and pipeline products. The Branded Generics business witnessed significant growth, with revenues growing more than tenfold YoY in Q2FY26. Strong product acceptance and customer adoption are driving this momentum. We are now approved and supplying to multiple large hospital chains across India, and we expect pan-India presence by the end of FY26. Operating cash flows continued to strengthen, rising over threefold to Rs 31 crore in H1FY26 from Rs 9 crore in H1FY25. We expect to maintain and build further on this trajectory going forward. All in all, we have delivered a healthy performance in the quarter and half year and remain on track to deliver on our full year guidance. Our business is undergoing a structural advancement which will provide better market visibility and support the growth momentum for us over the medium term to longer term. We will continue to drive the business on 4 key pillar. Expansion of the ANDA Portfolio in Regulated Markets. Steady Scale-up of the CDMO/CMO Segment in Regulated Markets. Portfolio Expansion and Profitability Improvement in Emerging Markets. Scale-up of Branded Generics business in India.” Result PDF